Abstract
18F-fluoro-ethyl-tyrosine (18F-FET) PET/CT as a potential new diagnostic tool in multiple myeloma: a preliminary study
- Department of Haematology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland
- Department of Nuclear Medicine, Professor Franciszek Lukaszczyk Oncology Centre in Bydgoszcz, Bydgoszcz, Poland
- Department of Haematology, Jagiellonian University Medical College, Krakow, Poland
- Department of Haematology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland
- Department of Oncology, Professor Franciszek Lukaszczyk Oncology Centre in Bydgoszcz, Bydgoszcz, Poland
- Department of Haematology, Dr. Jan Biziel University Hospital No. 2 in Bydgoszcz, Bydgoszcz, Poland
Aim of the study
The aim of this study was to analyse the diagnostic accuracy of “18F-fluoro-ethyl-tyrosine (18F-FET) PET/CT tracer in multiple myeloma.
Material and methods
The analysed group included: patients with newly diagnosed active myeloma (eight patients); in very good partial remission or complete remission (VGPR or CR) after treatment (nine patients); and with active disease after relapse (15 patients).
Results
In patients with newly diagnosed myeloma, 64 lesions were found using CT and 83 lesions using 18F-FET. In six patients, the number of lesions using CT and 18F-FET was the same, and two had more lesions with the 18F-FET than with the CT. Patients in VGPR or CR had no FET-positive lesions. Fourteen out of 15 patients with active relapsed myeloma had 47 FET-positive lesions, CT assessment of the same group showed 282 lesions. In one patient with relapse soft tissue mass was found with 18F-FET but not with CT.
Conclusions
18F-FET can be a promising alternative to 18F-FDG PET/CT for myeloma-related bone disease diagnosis.
Keywords
multiple myeloma, 18F-FET, 18F-FDG PET/CT
Coverage in
Indexed in
Integrated with
